TMCnet News
ITRI Startup DFON Biomedical Technology Unveils New Serum with MMpH+ to Fight Skin AgingTAIPEI, Taiwan, March 07, 2018 (GLOBE NEWSWIRE) -- DFON Biomedical Technology Inc., ITRI's first beauty care products startup, today (March 7) officially marked its inauguration and unveiled a new generation of products, demonstrating how innovative technology can be applied in the development of cosmetics and skin care products. DFON was founded on the basis of technology transferred from ITRI, with the key ingredient MMpH+ originally used in encapsulating cancer drugs. When researchers tested MMpH+ on the skin, they discovered its benefits in protecting the skin's collagen and serving as a moisturizer, thereby preventing wrinkles. The company thus launched the fourth generation anti-aging formula Enzyme Secret AP-I, which provides comprehensive skin protection and regeneration from the effects of aging, environmental factors, and sun damage. With its R&D expertise, DFON was selected to enter the Paris&Co business acceleration program. During trial operation, it sold over 1,000 units of its products. Even Jeanine (Chin Hsi), a Paris-based supermodel, is a fan of its Anti-Aging Serum. She tested her skin with an ultrasonic machine before using the product and saw considerable changes after two to three weeks of daily application. The serum helped retain collagen, making her skin become full of luster. This September DFON's products are expected to hit the shelves of France's pharmacy channel. According to ITRI's Industrial Economics and Knowledge Center, an Euromonitor report shows that the globa beauty and personal care market, which stood at NT$426.0 billion in 2015, is expected to expand to over NT$546.5 billion in 2020, with a compound annual growth of 5.1%. Local cosmetics brands have increasingly taken root in recent years. Taiwan's cosmetics product exports, according to the statistics from the Ministry of Economic Affairs, hit a new high of US$730 million in 2017, rising 13% over the previous year. This points to growing international interest in Taiwan's cosmetics brands. ITRI Commercialization and Industry Service Center General Director Jia-Ming Liu remarked that ITRI has consistently sought to nurture and incubate startup businesses to commercialize its R&D achievements. In this process, it engages in business planning and investment assessment for these enterprises. DFON, he said, not only is ITRI's first beauty care startup, but also in 2017 was selected to join Paris&Co, an economic development and innovation agency. With assistance from the French government, participants in Paris&Co have the opportunity to forge business relationships with and earn support from major corporations and venture capital banks in France, he said. About MMpH+ Active Ingredient in Collagen Regeneration About DFON Biomedical Technology Inc. DFON presently plans to launch its French cosmeceutical project with its Enzyme Secret AP-I anti-aging serum and anticipates having its products on the shelves of pharmacy channel by this September, following which it will expand its reach to Asia and the Americas through local distributors, demonstrating the R&D capabilities and international competitiveness of Taiwan's cosmetics and skin care products. More information about DFON is available at: http://www.dermafountain.com. DFON has created a Facebook page for its Enzyme Secret line of products at: https://www.facebook.com/enzymesecret/. About ITRI Over the years, ITRI has incubated over 300 innovative companies, including well-known names such as UMC and TSMC. In addition to its headquarters in Taiwan, ITRI has branch offices in the U.S., Europe, and Japan in an effort to extend its R&D scope and promote opportunities for international cooperation around the world. For more information, please visit http://www.itri.org/eng. Media Contact A photo accompanying this announcement is available at //www.globenewswire.com/NewsRoom/AttachmentNg/b804ca2b-b446-4148-9b88-9976b6a5bd0e A photo accompanying this announcement is available at //www.globenewswire.com/NewsRoom/AttachmentNg/9195a9be-c6d3-4ef2-aa48-a84d6c4c908f |